What Happened?
South San Francisco, CA-based Annexon Biosciences Promoted Ted Yednock as Executive Vice President and Chief Innovation Officer
About the Company
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.
About the Person
Ted Yednock is Executive Vice President and Chief Innovation Officer at Annexon Biosciences. Previously, Ted held various senior IT leadership roles in the industry.
Info Source
News
Short Profile